A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

Phase 1Not Yet RecruitingNCT07385248

Addpharma Inc.28 enrolled

Overview

The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastritis

Interventions

AD-229DRUG

AD-229 Oral Tablet

AD-2291DRUG

AD-2291 Oral Tablet

Eligibility

Sex: ALLMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit * The Age equal to or greater than 19 in healthy volunteers at the time of screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Outcomes

Primary Outcomes

Maximum concentration of drug in plasma (Cmax)

Cmax of AD-229

Time frame: pre-dose (0hour) to 72hours

Area under the plasma concentration-time curve during dosing interval (AUCt)

AUCt of AD-229

Time frame: pre-dose (0hour) to 72hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.